Should I buy or sell Kura Oncology stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares. View KURA analyst ratings or view top-rated stocks .

What is Kura Oncology's stock price target for 2024?

8 Wall Street research analysts have issued 1-year price targets for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $27.31 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View analysts price targets for KURA or view top-rated stocks among Wall Street analysts .

How have KURA shares performed in 2023?

Kura Oncology's stock was trading at $12.41 on January 1st, 2023. Since then, KURA shares have decreased by 12.9% and is now trading at $10.81. View the best growth stocks for 2023 here .

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our KURA earnings forecast .

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) released its earnings results on Thursday, November, 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.06.

What ETF holds Kura Oncology's stock ?

Simplify Propel Opportunities ETF holds 80,000 shares of KURA stock, representing 0.79% of its portfolio.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL) , Inovio Pharmaceuticals (INO) , Viking Therapeutics (VKTX) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Amarin (AMRN) , Gilead Sciences (GILD) , NVIDIA (NVDA) , Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD) .

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (5.89%), Armistice Capital LLC (3.01%), Affinity Asset Advisors LLC (1.15%), Northern Trust Corp (0.95%), Acuta Capital Partners LLC (0.95%) and Charles Schwab Investment Management Inc. (0.76%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Thomas James Doyle and Thomas Malley. View institutional ownership trends .

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Kura Oncology Stock Price, News & Analysis (NASDAQ:KURA)

$10.81

-0.49 (-4.34%)

(As of 12/8/2023 ET)

Compare

Today's Range: $10.40
▼
$11.44
50-Day Range: $7.58
▼
$11.30
52-Week Range: $7.41
▼
$15.50

Volume: 1.36 million shs
Average Volume: 685,951 shs
Market Capitalization: $802.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.31

Kura Oncology MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 152.7% Upside
$27.31 Price Target
Short Interest: Bearish
16.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.76
Upright™ Environmental Score
News Sentiment: -0.08
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.09) to ($2.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

849th out of 954 stocks

Biotechnology Industry

94th out of 111 stocks

3.4

Analyst's Opinion

Consensus Rating
Kura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.31, Kura Oncology has a forecasted upside of 152.7% from its current price of $10.81.
Amount of Analyst Coverage
Kura Oncology has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
16.52% of the float of Kura Oncology has been sold short.
Short Interest Ratio / Days to Cover
Kura Oncology has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Kura Oncology has recently increased by 7.62%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kura Oncology does not currently pay a dividend.
Dividend Growth
Kura Oncology does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Kura Oncology is -0.76.

1.6

News and Social Media Coverage

News Sentiment
Kura Oncology has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Kura Oncology this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
3 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kura Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.40% of the stock of Kura Oncology is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Kura Oncology are expected to decrease in the coming year, from ($2.09) to ($2.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kura Oncology is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kura Oncology is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kura Oncology has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kura Oncology Stock (NASDAQ:KURA)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

KURA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KURA Stock News Headlines

December 9, 2023 | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright

December 8, 2023 | stockhouse.com

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

December 9, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 28, 2023 | finance.yahoo.com

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

November 5, 2023 | finance.yahoo.com

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript

November 5, 2023 | benzinga.com

Kura Oncology Stock (NASDAQ:KURA), Analyst Ratings, Price Targets, Predictions

November 4, 2023 | markets.businessinsider.com

Scotiabank Reaffirms Their Hold Rating on Kura Oncology (KURA)

November 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Butterfly Network (BFLY) and Kura Oncology (KURA)

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 3, 2023 | msn.com

Kura Oncology files for $150M common stock offering, mixed securities shelf

November 3, 2023 | msn.com

Kura Oncology GAAP EPS of -$0.50 beats by $0.05

November 2, 2023 | seekingalpha.com

Kura Oncology, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 2, 2023 | finance.yahoo.com

Kura Oncology Inc (KURA) Reports Q3 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Kura Oncology Reports Third Quarter 2023 Financial Results

October 30, 2023 | finance.yahoo.com

Kura Oncology to Participate in Three Upcoming Investor Conferences

October 26, 2023 | finance.yahoo.com

Kura Oncology to Report Third Quarter 2023 Financial Results

October 20, 2023 | markets.businessinsider.com

Promising Clinical Trials and Underappreciated FTI Pipeline Justify Buy Rating for Kura Oncology

October 19, 2023 | msn.com

Wedbush Reiterates Kura Oncology (KURA) Outperform Recommendation

October 19, 2023 | stockhouse.com

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

October 19, 2023 | finance.yahoo.com

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

October 18, 2023 | msn.com

Kura aims FDA approval with positive data for tipifarnib in pivotal trial

October 18, 2023 | finanznachrichten.de

Kura Oncology, Inc.: Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

October 17, 2023 | finance.yahoo.com

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

October 9, 2023 | finance.yahoo.com

14 Best Cancer Stocks To Buy Now

October 4, 2023 | finance.yahoo.com

What Makes Kura Oncology (KURA) a New Buy Stock

October 4, 2023 | finance.yahoo.com

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 3, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Lantheus (LNTH), Kura Oncology (KURA)

See More Headlines

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KURA
CUSIP: N/A
CIK: 1422143
Web: www.kuraoncology.com
Phone: (858) 500-8800
Fax: N/A
Employees: 131
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.31
High Stock Price Target: $37.00
Low Stock Price Target: $10.50
Potential Upside/Downside: +152.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-135,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -33.54%
Return on Assets: -30.90%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 16.71
Quick Ratio: 16.71

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.28 per share
Price / Book: 1.72

Miscellaneous

Outstanding Shares: 74,272,000
Free Float: 70,113,000
Market Cap: $802.88 million
Optionable: Optionable
Beta: 0.68

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Troy E. Wilson
Chairman, President, CEO & Chief Financial Officer
Kathleen Ford
Chief Operating Officer
Stephen Dale
Chief Medical Officer
Mollie Leoni
Senior Vice President-Clinical Development
Brian T. Powl
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares.
View KURA analyst ratings or view top-rated stocks.
What is Kura Oncology's stock price target for 2024?: 8 Wall Street research analysts have issued 1-year price targets for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $27.31 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price.
View analysts price targets for KURA or view top-rated stocks among Wall Street analysts.
How have KURA shares performed in 2023?: Kura Oncology's stock was trading at $12.41 on January 1st, 2023. Since then, KURA shares have decreased by 12.9% and is now trading at $10.81.
View the best growth stocks for 2023 here.
When is Kura Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our KURA earnings forecast.
How were Kura Oncology's earnings last quarter?: Kura Oncology, Inc. (NASDAQ:KURA) released its earnings results on Thursday, November, 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.06.

What ETF holds Kura Oncology's stock ?: Simplify Propel Opportunities ETF holds 80,000 shares of KURA stock, representing 0.79% of its portfolio.
What other stocks do shareholders of Kura Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).
Who are Kura Oncology's major shareholders?: Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (5.89%), Armistice Capital LLC (3.01%), Affinity Asset Advisors LLC (1.15%), Northern Trust Corp (0.95%), Acuta Capital Partners LLC (0.95%) and Charles Schwab Investment Management Inc. (0.76%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Thomas James Doyle and Thomas Malley.
View institutional ownership trends.
How do I buy shares of Kura Oncology?: Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KURA) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial